SCHEMBL17232092

SCHEMBL17232092

COC[C@H]1O[C@@H](n2cnc(C(C)=O)n2)[C@H](F)[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ EIF4E P06730 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ TOP1 P11387 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ ADORA1 P30542 1/20 0.46
▸ THPO P40225 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ PNP P00491 3/20 0.40
▸ ATG7 O95352 5/20 0.39
▸ ADORA3 P0DMS8 1/20 0.37
▸ NT5E P21589 3/20 0.36
▸ CD99 P14209 1/20 0.36
▸ ADRB3 P13945 1/20 0.35
▸ TMEM97 Q5BJF2 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ ADK P55263 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15788414 0.90 LMNA (0.59) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL17232112 0.89 LMNA (0.57) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL17232095 0.88 PNP (0.46) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL15788460 0.85 PNP (0.59) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL18744095 0.79 LMNA (0.57) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL12151510 0.79 LMNA (0.73) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL17232105 0.77 PNP (0.57) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL12901991 0.75 LMNA (0.76) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL13320541 0.75 LMNA (0.76) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL2845582 0.75 LMNA (0.76) LMNASMN1; SMN2ALDH1A1GLAEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624249-B2 Nucleoside kinase bypass compositions and methods MERCK SHARP & DOHME CORP. (US) 2017-04-18 — — US disclosed
US-20150315221-A1 NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS MERCK SHARP & DOHME CORP. (US) 2015-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315221-A1 NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS DCK, DTYMK, TK1 LMNA 4073/4885SMN1; SMN2 3222/4885ALDH1A1 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback